
Quarterly report 2023-Q3
added 12-12-2023
Akumin EPS Ratio 2011-2026 | AKU
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Akumin
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.75 | -0.56 | -0.52 | -0.19 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.19 | -1.75 | -0.755 |
Quarterly EPS Ratio Akumin
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.9 | -1.07 | -0.39 | - | -0.6 | -0.34 | -0.35 | - | -0.02 | -0.1 | -0.04 | - | -0.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.02 | -1.07 | -0.391 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Diagnostics research industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-2.06 | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
-14.2 | $ 17.65 | 3.67 % | $ 186 M | ||
|
Agilent Technologies
A
|
3.98 | $ 118.32 | 0.66 % | $ 36 B | ||
|
Medpace Holdings
MEDP
|
15.6 | $ 428.14 | -0.51 % | $ 12.4 B | ||
|
Myriad Genetics
MYGN
|
-3.95 | $ 4.07 | -19.18 % | $ 377 M | ||
|
NeoGenomics
NEO
|
-0.84 | $ 8.89 | 0.28 % | $ 1.14 B | ||
|
National Research Corporation
NRC
|
50 | $ 18.05 | -3.68 % | $ 404 M | ||
|
Natera
NTRA
|
-5.57 | $ 217.23 | 5.06 % | $ 21.4 B | ||
|
Koninklijke Philips N.V.
PHG
|
3.67 | $ 27.01 | 2.1 % | $ 20 B | ||
|
Aspira Women's Health
AWH
|
-0.37 | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-0.14 | - | -61.36 % | $ 2.46 M | ||
|
Personalis
PSNL
|
-1.37 | $ 6.05 | 8.72 % | $ 358 M | ||
|
Biocept
BIOC
|
-1.89 | - | -13.05 % | $ 7.29 M | ||
|
Soleno Therapeutics
SLNO
|
0.4 | $ 52.93 | 0.01 % | $ 2.69 B | ||
|
CareDx, Inc
CDNA
|
-0.4 | $ 21.01 | 1.5 % | $ 1.12 B | ||
|
Chembio Diagnostics
CEMI
|
-0.72 | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
4.3 | - | - | $ 9.42 M | ||
|
HTG Molecular Diagnostics
HTGM
|
-24.3 | - | -20.0 % | $ 1.06 M | ||
|
Thermo Fisher Scientific
TMO
|
17.8 | $ 472.7 | 1.27 % | $ 178 B | ||
|
Co-Diagnostics
CODX
|
-35.2 | $ 1.61 | 0.94 % | $ 2.14 M | ||
|
Castle Biosciences
CSTL
|
0.66 | $ 25.04 | 1.79 % | $ 696 M | ||
|
Twist Bioscience Corporation
TWST
|
-1.3 | $ 59.96 | 5.75 % | $ 3.59 B | ||
|
Global Cord Blood Corporation
CO
|
4.12 | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
-0.08 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.08 | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
-3.09 | - | -11.32 % | $ 2.94 M | ||
|
Charles River Laboratories International
CRL
|
-2.91 | $ 185.16 | -0.12 % | $ 9.18 B | ||
|
Waters Corporation
WAT
|
3.78 | $ 351.2 | 2.5 % | $ 20.9 B | ||
|
Enzo Biochem
ENZ
|
-0.51 | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
-1.1 | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
-1.41 | $ 15.1 | 1.34 % | $ 457 M | ||
|
Guardant Health
GH
|
-3.32 | $ 92.05 | 2.83 % | $ 11.5 B | ||
|
Heska Corporation
HSKA
|
-1.92 | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
9.6 | $ 124.25 | 2.41 % | $ 10.2 B | ||
|
Illumina
ILMN
|
-7.69 | $ 141.7 | 1.89 % | $ 22.5 B | ||
|
Senseonics Holdings
SENS
|
-1.66 | $ 5.27 | 5.4 % | $ 220 M | ||
|
Interpace Biosciences
IDXG
|
5.55 | $ 2.01 | 0.1 % | $ 8.89 M | ||
|
QIAGEN N.V.
QGEN
|
1.96 | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
-2.16 | $ 2.16 | -1.14 % | $ 4.96 M | ||
|
Lantheus Holdings
LNTH
|
3.46 | $ 85.5 | -0.37 % | $ 5.77 B | ||
|
Laboratory Corporation of America Holdings
LH
|
10.5 | $ 257.05 | -0.04 % | $ 21.4 B | ||
|
Celcuity
CELC
|
-3.79 | $ 139.73 | -1.38 % | $ 6.53 B | ||
|
Motus GI Holdings
MOTS
|
-15.9 | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
-5.03 | $ 9.26 | -0.16 % | $ 2.01 B | ||
|
Quest Diagnostics Incorporated
DGX
|
8.87 | $ 189.71 | -0.59 % | $ 21.1 B |